Amgen Inc.
AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell counā¦ read more
Healthcare
Drug ManufacturersāGeneral
42 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$366.21
Price-0.43%
-$1.58
1Y
Price
Market Cap
$197.412b
Large
Price/Earnings 3y Avg5y Avg
25.7x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+51.3%
EBITDA Margin+13.5%
Net Profit Margin+9.7%
Free Cash Flow Margin+51.3%
EBITDA Margin+13.5%
Net Profit Margin+9.7%
Free Cash Flow MarginRevenue
$36.741b
+10.0%
1y CAGR+11.9%
3y CAGR+9.3%
5y CAGREarnings
$7.711b
+88.5%
1y CAGR+17.3%
3y CAGR+15.8%
5y CAGREPS
$14.23
+88.2%
1y CAGR+17.3%
3y CAGR+17.4%
5y CAGRBook Value
$8.658b
$90.586b
Assets$81.928b
Liabilities$54.604b
DebtDebt to Assets
60.3%
2.9x
Debt to EBITDAFree Cash Flow
$8.100b
-22.1%
1y CAGR+1.0%
3y CAGR+1.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company